PH.D in Immunopharmacology, Postdoctoral Fellow at Rochester University. Received grant from NIH/NCI Faculty Development Program and "2005 Excellent Award" from Rochester University.
Founded Hermed Capital in 2015, built and led the team completed the investment of Hermed Fund I since then.
A board member of Chongqing Fochon, Henlius (02696, HK), Beyond Spring Pharma (BYSI,NASD), Diamedica (DMAC, NASD). Aadi Bioscience and Applied Stemcell.
He was Deputy head of Fosun Pharma's H-share IPO team, advisor of Bio China and the member of the Investment subcommittee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA).
Prior to Hermed Capital, Jerry was the Vice President of Research Institute of Fosun Pharmaceutical (Group) Co., Ltd, responsible for BD and VC business of the group, successfully built the small molecule and large molecule platform for Fosun Pharma, and was responsible for the management and project licensing of R&D.
He led the establishment of Henlius (02696, HK) in December 2009, helping the team grow from a start-up to a unicorn, with more than 100 times return in 9 years.
In 2012, he invested in Beyond Spring Pharma in angel round, which has become Fosun Pharma's first NASDAQ-listed biopharmaceutical company (BYSI, NASDAQ, IPO in 2017). The company licensed out patent to Eli Lilly in 2020, with a total contract value of $790 million.
Mr. Yao Fang is the Senior Vice President and Co-CIO (Chief Investment Officer) of Fosun International.
Mr. Yao joined the Group in April 2010 and he has also been a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange). Prior to joining the Group, from 1993 to 2009, Mr. Yao was successively the assistant general manager of the international business department of Shanghai Wanguo Securities Company Limited, now known as Shenyin & Wanguo Securities Company Limited, general manager of Shanghai Industrial Assets Management Company Limited, general manager of Shanghai Industrial Management (Shanghai) Company Limited, managing director of Shanghai Industrial Pharmaceutical Investment Company Limited, a company delisted from the Shanghai Stock Exchange on 12 February 2010, chairman of Shanghai Overseas Company, non-executive director of Lianhua Supermarket Holdings Company Limited, a company listed on the Hong Kong Stock Exchange (stock code: 00980), and executive director of Shanghai Industrial Holdings Limited, a company listed on the Hong Kong Stock Exchange (stock code: 00363).
Mr. Yao was a non-executive director of BioSino Bio-Technology and Science Incorporation between 24 January 2011 to 13 March 2014, a company listed on the Hong Kong Stock Exchange (stock code: 08247).
Mr. Yao obtained a bachelor degree of economics from Fudan University in July 1989 and a master degree of business administration from The Chinese University of Hong Kong in December 1993.
Chairman & CEO, Dr. Jerry Xiao
Master degree in biochemistry and molecular biology, bachelor degree in pharmaceutical chemistry.
Over 20 years of professional career in pharmaceutical industry with deep rooted industrial knowledge and resources in China, seasoned experience in licensing, JV, M&A and investments with 20+ successful deals.
Joined Hermed Capital in 2015, Mr. Wu responsible for pharma and biotech investment, successfully completed 4 deals (Diamedica, Henlius, AADi and Hinvoa Pharma) and provided essential value-added support; Diamedica (DMAC, NASD) & Henlius (02696, HK) were listed by IPO; Hinova Pharma is in IPO process; AADi’s embedded value has grown significantly after submission of its first product to FDA.
Prior to joining Hermed Capital, Mr. Wu was the BD head of Kanghong Pharmaceutical (002773, SH); BD head and R&D director of Sichuan Hebang Group.
MBA degree in finance from Shanghai University of Finance and Economics; CFA Charter holder since 2006.
20 years of experiences in financial, portfolio management and risk control with extensive resources in financial industry.
Joined Hermed Capital in 2015, Mr. Zhao led financial and risk control team, in charge of financial and legal due diligence of all deals, involved in the negotiation, execution, portfolio management and exit.
Prior to joining Hermed Capital, Mr. Zhao has been working in MNCs for years, e.g. the investment director of SK (China), senior manager of PPF (China) Investment and credit rating analyst in DaGong Global Credit Rating Co., Ltd.
Mr. Zhao is currently a board member of Epic Sciences.
